INS and type 2 diabetes mellitus: Three trials included insulin-naive patients with T2D,[17,19,20] while 4 trials included basal insulin-treated patients with T2D.[10,11,18,21] Five trials evaluated the efficacy of Icodec[10,17–19,21] and 2 trials evaluated BIF.[11,20] One trial evaluated 3 different once-weekly insulin dosing schedules,[19] and 2 trials evaluated 2 once-weekly insulin dosing schedules.[11,18] Treatment lasted 16 weeks in 2 trials,[18,19] 26 weeks in 4 trials,[10,17,20,21] and 32 weeks in 1 trial[11] (Table 1).